BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

NCT06032936 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Business reason

Conditions

NSCLC

Interventions

DRUG: BBP-398
DRUG: osimertinib

Sponsor

LianBio LLC